Voya Investment Management LLC Raises Position in Axsome Therapeutics, Inc. (NASDAQ:AXSM)

Voya Investment Management LLC grew its position in shares of Axsome Therapeutics, Inc. (NASDAQ:AXSM) by 8.7% during the fourth quarter, according to the company in its most recent disclosure with the Securities & Exchange Commission. The fund owned 102,742 shares of the company’s stock after buying an additional 8,259 shares during the quarter. Voya Investment Management LLC’s holdings in Axsome Therapeutics were worth $8,693,000 as of its most recent filing with the Securities & Exchange Commission.

Other institutional investors and hedge funds also recently made changes to their positions in the company. Assetmark Inc. purchased a new stake in Axsome Therapeutics during the 4th quarter valued at $52,000. R Squared Ltd purchased a new stake in shares of Axsome Therapeutics during the fourth quarter valued at $64,000. KBC Group NV boosted its position in shares of Axsome Therapeutics by 40.5% during the fourth quarter. KBC Group NV now owns 1,336 shares of the company’s stock valued at $113,000 after buying an additional 385 shares during the last quarter. Xponance Inc. increased its holdings in Axsome Therapeutics by 11.6% in the 4th quarter. Xponance Inc. now owns 2,659 shares of the company’s stock worth $225,000 after buying an additional 277 shares in the last quarter. Finally, Intrust Bank NA raised its position in Axsome Therapeutics by 6.9% in the 4th quarter. Intrust Bank NA now owns 2,823 shares of the company’s stock worth $239,000 after buying an additional 183 shares during the last quarter. Institutional investors own 81.49% of the company’s stock.

Analyst Ratings Changes

A number of analysts have recently commented on the stock. Robert W. Baird lifted their price target on shares of Axsome Therapeutics from $132.00 to $160.00 and gave the stock an “outperform” rating in a research note on Monday, March 3rd. William Blair reaffirmed an “outperform” rating on shares of Axsome Therapeutics in a research report on Tuesday, February 18th. Morgan Stanley increased their price target on Axsome Therapeutics from $125.00 to $190.00 and gave the company an “overweight” rating in a report on Thursday, February 27th. Cantor Fitzgerald restated an “overweight” rating and issued a $153.00 price target on shares of Axsome Therapeutics in a research note on Wednesday, February 19th. Finally, HC Wainwright reiterated a “buy” rating and set a $200.00 price objective on shares of Axsome Therapeutics in a research report on Thursday, April 3rd. One investment analyst has rated the stock with a hold rating and sixteen have issued a buy rating to the company’s stock. According to data from MarketBeat.com, the company currently has an average rating of “Moderate Buy” and an average target price of $169.87.

Axsome Therapeutics Stock Up 2.5 %

NASDAQ AXSM opened at $109.92 on Wednesday. Axsome Therapeutics, Inc. has a 12 month low of $64.11 and a 12 month high of $139.13. The company has a current ratio of 2.11, a quick ratio of 2.04 and a debt-to-equity ratio of 3.22. The stock has a market cap of $5.36 billion, a PE ratio of -18.35 and a beta of 0.88. The stock’s 50 day moving average is $114.76 and its 200 day moving average is $103.42.

Axsome Therapeutics (NASDAQ:AXSM) last released its earnings results on Tuesday, February 18th. The company reported ($0.96) EPS for the quarter, topping the consensus estimate of ($0.97) by $0.01. The firm had revenue of $118.77 million for the quarter, compared to the consensus estimate of $117.83 million. Axsome Therapeutics had a negative net margin of 74.47% and a negative return on equity of 223.51%. Research analysts predict that Axsome Therapeutics, Inc. will post -2.79 EPS for the current fiscal year.

Insider Buying and Selling at Axsome Therapeutics

In related news, CFO Nick Pizzie sold 3,000 shares of the firm’s stock in a transaction on Friday, February 14th. The shares were sold at an average price of $131.07, for a total value of $393,210.00. Following the completion of the transaction, the chief financial officer now directly owns 42,187 shares of the company’s stock, valued at approximately $5,529,450.09. This trade represents a 6.64 % decrease in their ownership of the stock. The transaction was disclosed in a document filed with the SEC, which can be accessed through this hyperlink. Insiders own 22.40% of the company’s stock.

Axsome Therapeutics Company Profile

Axsome Therapeutics, Inc, a biopharmaceutical company, engages in the development of novel therapies for central nervous system (CNS) disorders in the United States. The company’s commercial product portfolio includes Auvelity (dextromethorphan-bupropion), a N-methyl-D-aspartate receptor antagonist with multimodal activity indicated for the treatment of major depressive disorder; and Sunosi (solriamfetol), a medication indicated to the treatment of excessive daytime sleepiness in patients with narcolepsy or obstructive sleep apnea.